Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid in Treating Cyanotic Breath Holding Spells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~1. Children with high frequency spells (≥ 4/week) of CBHS.~2. Children with parents who were wishing to provide treatment to their children.~3. Failure of alternatives modalities of treatment (e.g. iron supplements, piracetam, non-specific vitamins, etc) (tried for ≥ 3 months) to reduce the frequency of spells or stop them.~4. Follow-up for 6 months after starting treatment with valproic acid.~Exclusion criteria:~1. Primary neurologic disease, history of epilepsy or febrile convulsions, abnormal neurological examination and abnormal EEG.~2. Primary cardiac disease or presence of long QT syndrome in the ECG.~3. Presence of a hematologic (other than IDA) or other medical disease, electrolyte disturbance, hypoglycemia, hypocalcemia, impaired kidney or liver function tests.~4. Those with a doubtful diagnosis.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- cyanotic breath holding spells (Type: OTHER): drug, valproic acid: 5mg/kg/d for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).